Intravenous immunoglobulin-induced severe vesicular eczematous eruption successfully treated with narrow band-ultraviolet B therapy
© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd..
Intravenous immunoglobulins (IVIg) are increasingly being used to treat a wide spectrum of dermatological and neurological autoimmune diseases. Although the administration of IVIg does not usually result in severe adverse reactions, side effects of IVIg reportedly occur in 6-13% of patients. Most reported cases were not severe, and IVIg is considered a relatively safe drug. Some reports described a vesicular eczematous eruption caused by IVIg that was cured by applying topical steroid ointments or systemic steroids. Herein, we present, to the best of our knowledge, the first case of severe vesicular eczematous eruption all over the body induced by IVIg that was unresponsive to topical steroid ointment and was subsequently treated with narrow band-ultraviolet B (NB-UVB) therapy successfully. NB-UVB was started at a dose of 400 mJ/cm2 once a week, and swift improvement was observed. The skin rash disappeared in the first 2 months, and the pathogenesis of IVIg-induced eczematous eruption remains unelucidated. No change in eosinophils and complement levels were observed in our case. Given the increase in the widespread use of IVIg, we have shown that NB-UVB therapy is a candidate choice for the treatment of IVIg-induced severe vesicular eczematous eruption.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:37 |
|---|---|
| Enthalten in: |
Photodermatology, photoimmunology & photomedicine - 37(2021), 5 vom: 06. Sept., Seite 371-373 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Koizumi, Rina [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
CIDP |
|---|
| Anmerkungen: |
Date Completed 17.01.2022 Date Revised 17.01.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/phpp.12666 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM321197313 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM321197313 | ||
| 003 | DE-627 | ||
| 005 | 20231225175310.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/phpp.12666 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1070.xml |
| 035 | |a (DE-627)NLM321197313 | ||
| 035 | |a (NLM)33559335 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Koizumi, Rina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Intravenous immunoglobulin-induced severe vesicular eczematous eruption successfully treated with narrow band-ultraviolet B therapy |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.01.2022 | ||
| 500 | |a Date Revised 17.01.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. | ||
| 520 | |a Intravenous immunoglobulins (IVIg) are increasingly being used to treat a wide spectrum of dermatological and neurological autoimmune diseases. Although the administration of IVIg does not usually result in severe adverse reactions, side effects of IVIg reportedly occur in 6-13% of patients. Most reported cases were not severe, and IVIg is considered a relatively safe drug. Some reports described a vesicular eczematous eruption caused by IVIg that was cured by applying topical steroid ointments or systemic steroids. Herein, we present, to the best of our knowledge, the first case of severe vesicular eczematous eruption all over the body induced by IVIg that was unresponsive to topical steroid ointment and was subsequently treated with narrow band-ultraviolet B (NB-UVB) therapy successfully. NB-UVB was started at a dose of 400 mJ/cm2 once a week, and swift improvement was observed. The skin rash disappeared in the first 2 months, and the pathogenesis of IVIg-induced eczematous eruption remains unelucidated. No change in eosinophils and complement levels were observed in our case. Given the increase in the widespread use of IVIg, we have shown that NB-UVB therapy is a candidate choice for the treatment of IVIg-induced severe vesicular eczematous eruption | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a CIDP | |
| 650 | 4 | |a IVIg | |
| 650 | 4 | |a NB-UVB | |
| 650 | 4 | |a dermatological adverse reaction | |
| 650 | 4 | |a vesicular eczematous eruption | |
| 650 | 7 | |a Immunoglobulins, Intravenous |2 NLM | |
| 700 | 1 | |a Fukumoto, Takeshi |e verfasserin |4 aut | |
| 700 | 1 | |a Jimbo, Haruki |e verfasserin |4 aut | |
| 700 | 1 | |a Nishigori, Chikako |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Photodermatology, photoimmunology & photomedicine |d 1996 |g 37(2021), 5 vom: 06. Sept., Seite 371-373 |w (DE-627)NLM012810770 |x 1600-0781 |7 nnns |
| 773 | 1 | 8 | |g volume:37 |g year:2021 |g number:5 |g day:06 |g month:09 |g pages:371-373 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/phpp.12666 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 37 |j 2021 |e 5 |b 06 |c 09 |h 371-373 | ||